dc.contributor.author |
McNamara, Megan A |
|
dc.contributor.author |
Nair, Smita K |
|
dc.contributor.author |
Holl, Eda K |
|
dc.coverage.spatial |
Egypt |
|
dc.date.accessioned |
2017-06-16T19:51:12Z |
|
dc.date.available |
2017-06-16T19:51:12Z |
|
dc.date.issued |
2015 |
|
dc.identifier |
https://www.ncbi.nlm.nih.gov/pubmed/26665011 |
|
dc.identifier.uri |
https://hdl.handle.net/10161/14926 |
|
dc.description.abstract |
RNA vaccines traditionally consist of messenger RNA synthesized by in vitro transcription
using a bacteriophage RNA polymerase and template DNA that encodes the antigen(s)
of interest. Once administered and internalized by host cells, the mRNA transcripts
are translated directly in the cytoplasm and then the resulting antigens are presented
to antigen presenting cells to stimulate an immune response. Alternatively, dendritic
cells can be loaded with either tumor associated antigen mRNA or total tumor RNA and
delivered to the host to elicit a specific immune response. In this review, we will
explain why RNA vaccines represent an attractive platform for cancer immunotherapy,
discuss modifications to RNA structure that have been developed to optimize mRNA vaccine
stability and translational efficiency, and describe strategies for nonviral delivery
of mRNA vaccines, highlighting key preclinical and clinical data related to cancer
immunotherapy.
|
|
dc.language |
eng |
|
dc.publisher |
Hindawi Limited |
|
dc.relation.ispartof |
J Immunol Res |
|
dc.relation.isversionof |
10.1155/2015/794528 |
|
dc.subject |
Animals |
|
dc.subject |
Antigen Presentation |
|
dc.subject |
Antigens, Neoplasm |
|
dc.subject |
Cancer Vaccines |
|
dc.subject |
Clinical Trials as Topic |
|
dc.subject |
Cytotoxicity, Immunologic |
|
dc.subject |
Dendritic Cells |
|
dc.subject |
Disease Models, Animal |
|
dc.subject |
Humans |
|
dc.subject |
Lymphocyte Activation |
|
dc.subject |
Neoplasms |
|
dc.subject |
RNA, Messenger |
|
dc.title |
RNA-Based Vaccines in Cancer Immunotherapy. |
|
dc.type |
Journal article |
|
duke.contributor.id |
Nair, Smita K|0114773 |
|
duke.contributor.id |
Holl, Eda K|0456028 |
|
pubs.author-url |
https://www.ncbi.nlm.nih.gov/pubmed/26665011 |
|
pubs.begin-page |
794528 |
|
pubs.organisational-group |
Clinical Science Departments |
|
pubs.organisational-group |
Duke |
|
pubs.organisational-group |
Duke Cancer Institute |
|
pubs.organisational-group |
Institutes and Centers |
|
pubs.organisational-group |
Pathology |
|
pubs.organisational-group |
School of Medicine |
|
pubs.organisational-group |
Surgery |
|
pubs.organisational-group |
Surgery, Surgical Sciences |
|
pubs.publication-status |
Published |
|
pubs.volume |
2015 |
|
dc.identifier.eissn |
2314-7156 |
|
duke.contributor.orcid |
Nair, Smita K|0000-0001-7019-1912 |
|
duke.contributor.orcid |
Holl, Eda K|0000-0002-6975-3647 |
|